These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 23647206

  • 1. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, Giunta A, Vena GA, Chimenti S, Girolomoni G.
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [Abstract] [Full Text] [Related]

  • 2. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R, Kragballe K, Dam TN, Skov L.
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [Abstract] [Full Text] [Related]

  • 3. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 4. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM, van Lümig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W, de Jong EM.
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [Abstract] [Full Text] [Related]

  • 5. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Apr; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

  • 7. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L.
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [Abstract] [Full Text] [Related]

  • 8. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 9. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA).
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ, Poon KY, Bebchuk JD.
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 14. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Oct; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 15. Treatment of generalized vitiligo with anti-TNF-α Agents.
    Alghamdi KM, Khurrum H, Taieb A, Ezzedine K.
    J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
    [Abstract] [Full Text] [Related]

  • 16. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J, Burden AD.
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [Abstract] [Full Text] [Related]

  • 17. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH, Knoop C, Enk AH, Hadaschik EN.
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Dec; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 19. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.